. The exfoliation enabled by the graphene interlayer differs from typical methods 9, 10 , which require the chemical etching of a sacrificial layer and/or mechanical polishing of the substrate to afford a smooth surface for subsequent epitaxial growth. It is also worth noting that the graphene-coated GaAs substrates can be reused for epitaxy. Given that substrates of GaAs and other semiconductors can be expensive, the ability to reuse substrates could create substantial cost savings in applications that involve large areas, such as high-efficiency solar cells.
Some hurdles remain before Kim and colleagues' epitaxial process is ready for commercial application. First, although the researchers show that the surfaces of the epitaxially grown GaAs films are smooth on the micrometre scale, they are not uniformly smooth over large areas (square millimetres). Second, any defects present in the graphene interlayer cause damage to the substrate and the film during exfoliation. Moreover, the authors prepared epitaxial templates by transferring previously prepared graphene onto GaAs substrates. A process for directly forming single layers of graphene on GaAs could greatly simplify things, and might allow larger, more uniform GaAs films to be made. Work will also be needed to show that devices with state-of-the-art performance can be made, such as low-threshold lasers or high-efficiency solar cells.
In addition to positioning remote epitaxy as a new mode of crystal growth, Kim 
Two-for-one on potential therapies
Molecules that inhibit the synthesis of the ataxin 2 protein can ameliorate the effects of two neurodegenerative diseases in mouse models, raising hopes for the success of this approach in clinical trials. See Letters p.362 & p.367
eurodegenerative disorders can be devastating, and many lack effective treatments. One possible therapeutic strategy involves the use of antisense oligo nucleotides (ASOs) -short stretches of nucleotides that bind to a messenger RNA and inhibit its translation into protein. Support for this idea is provided by two papers in this issue 1, 2 , which report that ASOs that target mRNA translated into the ataxin 2 protein can ameliorate movement defects in mouse models of neurodegenerative disease.
In the first study, Scoles et al. 1 (p. 362) investigated the use of ASOs to tackle a disease called spinocerebellar ataxia type 2, in which mutations in ataxin 2 cause neurodegeneration. This leads to neuronal abnormalities, including decreases in the firing of neurons called Purkinje cells in the brain's cerebellum, and to motor defects, which affect movement 3 ( Fig. 1a) . The authors began by screening 152 ASOs in vitro, to identify those that reduced cellular levels of ataxin 2 mRNA most efficiently.
Next, they injected this molecule into two different mouse models of spinocerebellar ataxia type 2, both of which had been genetically engineered to express a mutated form of human ataxin 2. The mutant mice exhibit deterioration in movement during adulthood, mimicking the human disease. However, ASO injection into the animals' brain and cerebrospinal fluid lowered the levels of ataxin 2 protein in these regions. As a result, the decline of the creatures' motor performance was significantly slowed compared with untreated controls.
Scoles and colleagues went on to investigate the molecular mechanisms underlying this improvement. They found that abnormal mechanism by which this rescue might occur. Ataxin 2 is required for the formation of specialized, cytoplasmic RNA-protein complexes called stress granules, which form when cellular stress inhibits translation. TDP-43 is recruited to stress granules, and this recruitment has been suggested to have a crucial role in ALS development, because it initiates the accumulation of TDP-43 into toxic aggregates 7 (Fig. 1b) . The researchers showed that lowering levels of ataxin 2 in human cells in vitro strongly inhibited both the assembly of stress granules and TDP-43 aggregation. Finally, Becker et al. injected an ASO that binds ataxin 2 into mice harbouring the aggregated human TDP-43. The treatment extended the animals' lifespan and delayed motor deterioration compared with untreated counterparts.
It is to be hoped that these preclinical successes can be translated to use in patients. Although such translation of neurological therapies that showed promise in mice has often failed, there have also been successesas exemplified by ASO therapy for spinal muscular atrophy. In an approach not unlike that proposed by the current two papers, highly specific ASO treatment is now saving the lives of young children with spinal muscular atrophy 8 . This advance was made possible by basic research that provided a true understanding of the disease, leading to the targeting of the mutant gene that triggers its initiation, and by the effective use of various preclinical models, including a mouse model 9 , to develop the ASO therapy 10 . There is no reason that the current studies should not provide a comparable foundation for ASO therapy in spinocerebellar ataxia type 2 and in TDP-43-mediated neurodegenerative diseases such as ALS.
Naturally, there are caveats that must be addressed. For instance, if ASOs are used to treat spinocerebellar ataxia type 2 in adults, decades after neurodegeneration begins, will the intervention be too late? It is certainly possible that destructive events -among others, abnormal activation of immune cells called microglia, the conversion of supporting astroglial cells into neuron-killing cells, and cell death -that would minimize ASO efficacy could have occurred by this stage. This is a major question in neurodegenerativedisease therapy. Regardless of the answer, it will be important to design clinical trials that aim to intervene as early as possible in disease progression.
Translation of ataxin 2 ASO treatment is likely to be more complex for ALS than for spinocerebellar ataxia type 2. Before the approach is trialled in humans, it should be tested in animal models on the basis of the genetic mutations that drive TDP-43 aggregation and ALS in humans, which Becker and colleagues' model was not. For example, mice harbouring a mutation dubbed C9orf72, which accounts for many ALS cases, exist and could be tested. Work with cell-based models that use cells derived from people with ALS could also be worthwhile.
The co-development of markers of drug action will also be necessary, because these will be crucial for testing therapies in diseases such as ALS. Measurements of ataxin 2 in the cerebrospinal fluid could, for instance, show whether an ASO is acting at its target to lower protein levels in the brain. Too many trials for neurological-disease therapies, including some for ALS, have been carried out without such markers. When these trials fail, researchers are left with no information as to why.
Nevertheless, these two papers herald a new wave of valuable preclinical research. They engender high hopes for the effectiveness of these ASOs -and perhaps other ASO expression of six key genes in the Purkinje cells of the mutant mice was reversed by ASO injection, suggesting that the molecule's effect is due, at least in part, to correction of transcriptional dysregulation. In addition, the injection restored the physiological activity of Purkinje cells. Given the tight link between Purkinje-cell physiology and motor behaviour, the researchers argue that the ASO treatment delays disease progression, at least in part, by ameliorating defects in this neuronal population.
In the second study, Becker et al. 2 (p. 367) investigated another neurodegenerative disease, amyotrophic lateral sclerosis (ALS, also known as motor neuron disease). Ataxin 2 mutations do not cause ALS, but can increase the risk of its occurrence, suggesting that these mutations do contribute to ALS in some way. Indeed, a previous study 4 in yeast by the group that performed the current work identified ataxin 2 as a potent modifier of the toxicity caused by another protein, TDP-43. More than 95% of ALS cases involve abnormal aggregation of this nuclear protein into harmful clumps in the cell cytoplasm. TDP-43 is essential for life, so treatments that target it directly are not viable 5 . However, deletion of ataxin 2 has few harmful effects in mice 6 . Therefore, ataxin 2 is expected to be a more promising target for ALS therapies.
Becker and colleagues showed that deletion of ataxin 2 significantly extends the shortened lifespan of an ' ALS-like' mouse model that harbours aggregates of human TDP-43. The treatment also improves motor function and reduces neuronal degeneration in the brain's cortex.
The authors next investigated the 1 studied mice that harboured the disease-causing human gene, injecting them with an antisense oligonucleotide (ASO) molecule that binds to ataxin 2 messenger RNA and inhibits its translation. The treatment ameliorates the effects of the disease. b, Ataxin 2 also promotes the assembly of cytoplasmic RNA-protein complexes called stress granules, in which the protein TDP-43 aggregates to form toxic clumps. This aggregation is thought to contribute to the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Becker et al. 2 show that an ataxin 2 ASO extends lifespan and slows motor deterioration in mice that carry an aggregation-prone human TDP-43 protein.
